Exposure of perfluorononanoic acid suppresses the hepatic insulin signal pathway and increases serum glucose in rats

Toxicology

Volumn 294, Issue 2-3, 2012, Pages 109-115

  Fang, Xuemei ^a,b,c   Gao, Guizhen ^a   Xue, Hongyu ^a   Zhang, Xingtao ^a   Wang, Haichao ^a  

^a SUZHOU UNIVERSITY   (China)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^c Dalian SEM Bioengineer and Biotech Ltd   (China)

Author keywords

Glucose metabolism; Glycogen; Insulin signal; Oxidative stress; Perfluorononanoic acid

Indexed keywords

GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 2; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN PEROXIDE; INSULIN; MALONALDEHYDE; PERFLUORONONANOIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN BLOOD LEVEL; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; GENE EXPRESSION REGULATION; GLYCOGEN; HYDROGEN PEROXIDE; INSULIN; LIVER; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

ANIMALIA; RATTUS;

EID: 84862806756     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.02.008     Document Type: Article

References (59)

1. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R.J., Reese C.B., Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. Curr. Biol. 1997, 7:261-269.
2. Bashan N., Kovsan J., Kachko I., Ovadia H., Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol. Rev. 2009, 89:27-71.
3. Berthiaume J., Wallace K.B. Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol. Lett. 2002, 129:23-32.
4. Bijland S., Rensen P.C., Pieterman E.J., Maas A.C., van der Hoorn J.W., van Erk M.J., Havekes L.M., Willems van Dijk K., Chang S.C., Ehresman D.J., Butenhoff J.L., Princen H.M. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. Toxicol. Sci. 2011, 123:290-303.
5. Birnbaum M.J. Turning down insulin signaling. J. Clin. Invest. 2001, 108:655-659.
6. Bjork J.A., Butenhoff J.L., Wallace K.B. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology 2011, 288:8-17.
7. Carroll N.V., Longley R.W., Roe J.H. The determination of glycogen in liver and muscle by use of anthrone reagent. J. Biol. Chem. 1956, 220:583-593.
8. Curran I., Hierlihy S.L., Liston V., Pantazopoulos P., Nunnikhoven A., Tittlemier S., Barker M., Trick K., Bondy G. Altered fatty acid homeostasis and related toxicologic sequelae in rats exposed to dietary potassium perfluorooctanesul-fonate (PFOS). J. Toxicol. Environ. Health A 2008, 71:1526-1541.
9. DePierre J.W. Effects on rodents of perfluorofatty acids. The Handbook of Environmental Chemistry 2002, vol. 3N. p. 494, doi:10.1007/10721878_7.
10. Ding L., Hao F., Shi Z., Wang Y., Zhang H., Tang H., Dai J. Systems biological responses to chronic perfluorododecanoic acid exposure by integrated metabonomic and transcriptomic studies. J. Proteome Res. 2009, 8:2882-2891.
11. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Are oxidative stress activated signaling pathways mediators of insulin resistance and cell dysfunction?. Diabetes 2003, 52:1-8.
12. Farese R.V., Sajan M.P., Standaert M.L. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp. Biol. Med. (Maywood) 2005, 230:593-605.
13. Frame S., Cohen P., Biondi R.M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell. 2001, 7:1321-1327.
14. Gilliland F.D., Mandel J.S. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am. J. Ind. Med. 1996, 29:560-568.
15. Gopaul N.K., Manraj M.D., Hebe A., Lee Kwai Yan S., Johnston A., Carrier M.J., Anggard E.E. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001, 44:706-712.
16. Guruge K.S., Taniyasu S., Yamashita N., Wijeratna S., Mohotti K.M., Seneviratne H.R., Kannan K., Yamanaka N., Miyazaki S. Perfluorinated organic compounds inhuman blood serum and seminal plasma: a study of urban and rural tea worker populations in Sri Lanka. J. Environ. Monit. 2005, 7:371-377.
17. Guruge K.S., Yeung L.W., Yamanaka N., Miyazaki S., Lam P.K., Giesy J.P., Jones P.D., Yamashita N. Gene expression profiles in rat liver treated with perfluorooctanoic acid (PFOA). Toxicol. Sci 2006, 89:93-107.
18. Hagenaars A., Knapen D., Meyer I.J., van der Ven K., Hoff P., De Coen W. Toxicity evaluation of perfluorooctane sulfonate (PFOS) in the liver of common carp (Cyprinus carpio). Aquat. Toxicol. 2008, 88:155-163.
19. Hart K., Gill V.A., Kannan K. Temporal trends (1992-2007) of perfluorinated chemicals in Northern Sea Otters (Enhydra lutris kenyoni) from South-Central Alaska. Arch. Environ. Contam. Toxicol. 2009, 56:607-614.
20. Haug L.S., Thomsen C., Becher G. Time trends and the infuence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. Environ. Sci. Technol. 2009, 43:2131-2136.
21. Haughom B., Spydevold O. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim. Biophys. Acta 1992, 1128:65-72.
22. Hill M.M., Clark S.F., Tucker D.F., Birnbaum M.J., James D.E., Macaulay S.L. A role for protein kinase β/Akt2 in insulin-stimulated Glut4 translocation in adipocytes. Mol. Cell. Biol. 1999, 19:7771-7781.
23. Hoff P.T., Van de Vijver K., Dauwe T., Covaci A., Maervoet J., Eens M., Blust R., De Coen W. Evaluation of biochemical effects related to perfluorooctane sulfonic acid exposure in organohalogen-contaminated great tit (Parus major) and blue tit (Parus caeruleus) nestlings. Chemosphere 2005, 61:1558-1569.
24. Houde M., Martin J.W., Letcher R.J., Solomon K.R., Muir D.C. Biological monitoring of polyfluoroalkyl substances: a review. Environ. Sci. Technol. 2006, 40:3463-3473.
25. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
26. Hu X.Z., Hu D.C. Effects of perfluorooctanoate and perfluorooctane sulfonate exposure on hepatoma Hep G2 cells. Arch. Toxicol. 2009, 83:851-861.
27. Im S.S., Kim M.Y., Kwon S.K., Kim T.H., Bae J.S., Kim H., Kim K.S., Oh G.T., Ahn Y.H. Peroxisome proliferator-activated receptor {alpha} is responsible for the up-regulation of hepatic glucose-6-phosphatase gene expression in fasting and db/db mice. J. Biol. Chem. 2011, 286:1157-1164.
28. Iynedjian P.B. Mammalian glucokinase and its gene. Biochem. J. 1993, 293(Pt 1):1-13.
29. Iynedjian P.B., Marie S., Gjinovci A., Genin B., Deng S.P., Buhler L., Morel P., Mentha G. Glucokinase and cytosolic phosphoenolpyruvate carboxykinase (GTP) in the human liver. Regulation of gene expression in cultured hepatocytes. J. Clin. Invest. 1995, 95:1966-1973.
30. Kannan K., Corsolini S., Falandysz J., Fillmann G., Kumar K.S., Loganathan B.G., Mohd M.A., Olivero J., Van Wouwe N., Yang J.H., Aldoust K.M. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ. Sci. Technol. 2004, 38:4489-4495.
31. Kärrman A., Ericson I., van Bavel B., Darnerud P.O., Aune M., Glynn A., Lignell S., Lindström G. Exposure of perfluorinated chemicals through lactation: levels of matched human milk and serum and a temporal trend, 1996-2004, in Sweden. Environ. Health Perspect. 2007, 115:226-230.
32. Kleszczyński K., Gardzielewski P., Mulkiewicz E., Stepnowski P., Składanowski A.C. Analysis of structure-cytotoxicity in vitro relationship (SAR) for perfluorinated carboxylic acids. Toxicol. In Vitro 2007, 21:1206-1211.
33. Kohn A.D., Takeuchi F., Roth R.A. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J. Biol. Chem. 1996, 271:21920-21926.
34. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 2007, 99:366-394.
35. Leonard R.C., Kreckmann K.H., Sakr C.J., Symons J.M. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann. Epidemiol. 2008, 18:15-22.
36. Lewis G.F., Carpentier A., Adeli K., Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 2002, 23:201-229.
37. Lin C.Y., Chen P.C., Lin Y.C., Lin L.Y. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care 2009, 32:702-707.
38. Liu W., Chen S., Harada K.H., Koizumi A. Analysis of perfluoroalkyl carboxylates in vacuum cleaner dust samples in Japan. Chemosphere 2011, 85:1734-1741.
39. -ΔΔCt method. Methods 2001, 25:402-408.
40. Livingstone D.R. Contaminant-stimulated reactive oxygen species production and oxidative damage in aquatic organisms. Mar. Pollut. Bull. 2001, 42:656-666.
41. MacNeil J., Steenland N.K., Shankar A., Ducatman A.A. Cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ. Res. 2009, 109:997-1003.
42. Nakae J., Kitamura T., Silve r D.L., Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 2001, 108:1359-1367.
43. Nilsen A.J., Landin M.A., Haug K.H., Fonnum F., Berger U., Osmundsen H. Comparative hepatic gene expression profiling of rats treated with 1H,1H,2H,2H- heptadecafluorodecan-1-ol or with pentadecafluorooctanoic acid. Physiol. Genomics 2008, 34:285-303.
44. O'Brien R.M., Granner D.K. Regulation of gene expression by insulin. Physiol. Rev. 1996, 76:1109-1161.
45. Ohmori K., Kudo N., Katayama K., Kawashima Y. Comparison of the toxicokinetics between perfluorocarboxylic acids with different carbon chain length. Toxicology 2003, 84:135-140.
46. Olsen G.W., Zobel L.R. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int. Arch. Occup. Environ. Health 2007, 81:231-246.
47. Puigserver P., Rhee J., Donovan J., Walkey C.J., Yoon J.C., Oriente F., Kitamura Y., Altomonte J., Dong H., Accili D., Spiegelman B.M. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003, 423:550-555.
48. Raz I., Eldor R., Cernea S., Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab. Res. Rev. 2005, 21:3-14.
49. Rotander A., Kärrman A., Bavel B.V., Polder A., Rigét F., Au{eth}unsson G.A., Víkingsson G., Gabrielsen G.W., Bloch D., Dam M. Increasing levels of long-chain perfluorocarboxylic acids (PFCAs) in Arctic and North Atlantic marine mammals, 1984-2009. Chemosphere 2011, doi:10.1016/j.
50. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
51. Sanguinetti S.M., Brites F.D., Fasulo V., Verona J., Elbert A., Wikinski R.L., Schreier L.E. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients. Diabetes Nutr. Metab. 2001, 14:27-36.
52. Seacat A.M., Thomford P.J., Hansen K.J., Olsen G.W., Case M.T., Butenhoff J.L. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci. 2002, 68:249-264.
53. Shi X., Du Y., Lam P.K.S., Wu R.S.S., Zhou B. Developmental toxicity and alteration of gene expression in zebrafish embryos exposed to PFOS. Toxicol. Appl. Pharmacol. 2008, 230:23-32.
54. So M.K., Yamashita N., Taniyasu S., Jiang Q., Giesy J.P., Chen K., Lam P.K. Health risks in infants associated with exposure to perfluorinated compounds in human breast milk from Zhoushan, China. Environ. Sci. Technol. 2006, 40:2924-2929.
55. Tanti J.F., Grillo S., Grémeaux T., Coffer P.J., Van Obberghen E., Le Marchand-Brustel Y. Potential role of protein kinase B in glucose transporter 4 translocation in adipocytes. Endocrinology 1997, 138:2005-2010.
56. Wang M., Park J.S., Petreas M. Temporal changes in the levels of perfluorinated compounds in California women's serum over the past 50 years. Environ. Sci. Technol. 2011, 45:7510-7516.
57. Wei Y., □Shi X., Zhang H., Wang J., Zhou B., Dai J. Combined effects of polyfluorinated and perfluorinated compounds on primary cultured hepatocytes from rare minnow (Gobiocypris rarus) using toxicogenomic analysis. Aquat. Toxicol. 2009, 95:27-36.
58. Yamashita N., Kannan K., Taniyasu S., Horii Y., Petrick G., Gamo T. A global survey of perfluorinated acids in oceans. Mar. Pollut. Bull. 2005, 51:658-668.
59. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., Shuldiner A.R., Fried S.K., McLenithan J., Gong D.W. Identification of omentin as a novel depotspecific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. 2006, 290:E1253-E1261.